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Abstract
Urinary stone disease, particularly calcium oxalate, is common in both humans and cats.
Calcifying nanoparticles (CNP) are spherical nanocrystallite material, and are composed of
proteins (fetuin, albumin) and inorganic minerals. CNP are suggested to play a role in a wide
array of pathologic mineralization syndromes including urolithiasis. We documented the
development of a clinically relevant protocol to assess urinary CNP in 9 healthy cats con-
suming the same diet in a controlled environment using Nanoparticle Tracking Analysis
(NTA®). NTA® is a novel method that allows for characterization of the CNP in an efficient,
accurate method that can differentiate these particles from other urinary submicron particu-
lates. The predominant nanoscale particles in feline urine are characteristic of CNP in terms
of their size, their ability to spontaneously form under suitable conditions, and the presence
of an outer layer that is rich in calcium and capable of binding to hydroxyapatite binders
such as alendronate and osteopontin. The expansion of this particle population can be sup-
pressed by the addition of citrate to urine samples. Further, compounds targeting exosomal
surfaces do not label these particulates. As CNP have been associated with a number of
significant urologic maladies, the method described herein may prove to be a useful adjunct
in evaluating lithogenesis risk in mammals.
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Introduction
Urinary tract stone formation is an ancient disease process with a recently reported prevalence
of up to 20% in adults in developed nations [1]. In many parts of the world, the prevalence of
urolithiasis increased during the latter portion of the 20th century[2,3] and can result in numer-
ous hospital visits, surgeries, and interventional procedures for the patient. Urolithiasis in cats is
also a frequently encountered disease, and the most common urolith type in both cats and
humans is calcium oxalate (CaOx) [4,5]. Relative risk factors for CaOx are similar between the
two species and include male predisposition, decreased fluid intake, and highly acidified urine
[6,7]. Furthermore, humans and cats are reported to have idiopathic hypercalciuria as a meta-
bolic feature in this disease[8,9]. Pharmacologic management strategies for both species have
yielded variable results[10–13]. Overall, high recurrence rates are problems in both species
[14,15].
To date, studies of the physical formation of CaOx have primarily focused on processes
relating to mineral or mineral-organic crystallization, nucleation, crystal growth, and aggrega-
tion. However, protein inhibitors of crystallization can bind mineral in an alternative insoluble
form. These forms represent colloidal suspensions of protein-mineral aggregates that may
have crystalline layers, but are not uniform crystal lattices and form by different mechanisms.
These protein-mineral complexes, or calcifying nanoparticles (CNP), are spherical nanocrys-
tallite material composed of biomineral and are 80–90 nm in diameter in their most stable
(primary) form[16]; larger, less stable, secondary CNP have also been reported to occur under
various conditions. CNP are composed of proteins (fetuin, albumin) and inorganic minerals
[17] and are suggested to play a role in a wide array of pathologic mineralization syndromes
including urolithiasis. CNP have been isolated from uroliths by several groups and are associ-
ated with the presence of renal papillary calcification (i.e. Randall’s plaques) in humans that
form CaOx uroliths[18–24]. CNP formation, size distribution, and stability are all dependent
on chemical factors in solution, many of which are often altered in the urine [17].
The overall small size distribution of primary as well as larger secondary CNP precludes
accurate characterization with traditional flow cytometric methods. Electron microscopy has
been considered the gold standard for visualization of CNP, and several other methods for
detection have also been used including ELISA, immunohistochemistry, immunofluorescence,
immunoblotting, and Ouchterlony immunodiffusion. However, none of these methods are
suitable for detailing both the size and surface characteristics of CNP in urine samples. Nano-
particle Tracking Analysis (NTA1; Malvern Instruments) is a novel method that allows for
the characterization of submicron particulates based on their Brownian movement [25–30].
NTA1 has been applied to exosome research, but the authors are unaware of published studies
in which NTA1 has been used to identify, or characterize CNP. Therefore, the goals of this
study were to demonstrate that feline urine CNP can be characterized, identified, and enumer-
ated using NTA1. We document the development of a clinically relevant protocol to assess
urinary CNP in 9 healthy cats consuming the same diet in a controlled environment.
Materials and Methods
Animals and urine sample collection/processing
The urine of nine (3 neutered male and 6 intact female) specific-pathogen free, healthy, adult
domestic shorthair cats were used in this study. The average (range) age, body weight and
body condition score of the female cats was 8.75 yr (6.5–10.75 yr), 4.32 kg (2.63–5.88 kg), and
6.75 (6.5–7.5 on a 9 point scale), respectively. The average (range) age, body weight and body
condition score of the male cats was 6.54 yr (5.33–7.33 yr), 5.99 kg (5.63–6.48 kg), and 5.2
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(3.5–8 on a 9 point scale), respectively. The urine samples had been saved from a separate,
unrelated study, during which cats were housed at the University of California, Davis. The
facility maintained room temperatures between 18–24˚C and had a 14 h light/10 h dark cycle.
All cats had been fed the same dry maintenance diet (Science Diet1 Adult Light; Hill’s1 Pet
Nutrition Inc. Topeka, KS, USA) to maintain appropriate body condition for 4 weeks prior to
urine collection by natural voiding. The experimental protocol was approved by the Institu-
tional Animal Care and Use Committee at the University of California, Davis (Animal Welfare
Assurance Number A3433-01) and the Royal Canin Ethics committee complied with the rec-
ommendations of the 2011 National Research Council Guide for the Care and Use of Labora-
tory Animals (The National Academies Press, Washington DC).
Voided urine samples were collected from the cats during individual housing and then
placed into sterile centrifuge tubes and maintained at 4 deg C until analysis. Urine was centri-
fuged at 1500 xG for 5 minutes then sterile filtered through a 0.22 um syringe filter prior to
storage. Aliquots were stored at 4, -20, and -80 deg C. Refrigerated samples were split into two
with one fraction having no additives and another containing 109 mmol/L of the dihydrate
form of trisodium citrate Na3C6H5O7 2H20 as a calcium-chelating agent.
CNP Stock Solution Standards-In vitro generation
Positive control suspensions consisted of CNP stock solutions generated using previously pub-
lished protocols[16]. In brief, CNP can be generated on the benchtop by the careful mixture of
three stock solutions: Stock solution 1 was a NaCl solution: 140 mM NaCl, Stock solution 2
was a calcium solution: 40 mM CaCl2 +100 mM Hepes +140 mM NaCl pH-adjusted with 10
M NaOH to 7.40 at 37˚C; Stock solution 3 was a phosphate solution: 19.44 mM Na2HPO4 +
4.56 mM NaH2PO4 + 100 mM Hepes + 140 mM NaCl pH-adjusted with 10 M NaOH to 7.40
at 37˚C. Calcified nanoparticle formation was induced by mixing reagents in the following
sequence at 37˚C: (1) NaCl solution: 20 volumes, (2) fetuin-A [0.1%]: 80 volumes, (3) shaking
for 1 minute, (4) phosphate solution: 50 volumes, (5) shaking for 1 minute, and (6) calcium
solution: 50 volumes and shaking for 1 minute. All chemicals, including lyophilized fetuin-A
derived from fetal calf serum, were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Nanoparticle Tracking Analysis
Calcified nanoparticles in the whole urine samples and in vitro generated CNP suspensions
were analyzed using the NanoSight LM10HS-48814TS instrument (Malvern Instruments,
Worcestershire, UK) with a 488 nm wavelength laser, fluorescent filter (505 nm long pass),
and both temperature control and syringe pump modules. The analysis settings were opti-
mized and kept constant between samples, and each video was analyzed to give the mean,
mode, median, and estimated concentration for each particle size. Advanced script control
options were used for each analysis which encompassed an 80 uL syringe pump driven cham-
ber-priming interval, a 30 second pause to minimize vibration artifact, three 60 second video
capture periods with constant syringe pump-driven sample delivery, and automated laser and
pump shutdown after video acquisition. Samples were analyzed with fluorescent filter in-line
only when fluorophores had been applied to the sample for surface labeling. Following pub-
lished methods for NTA characterization of urine exosomes[31] and initial pilot studies com-
paring whole urine samples and 1:1000 dilution, all experiments were carried out at a 1:1000
dilution, yielding particle concentrations in the region of 1 x108 particles/ml in accordance
with the manufacturer’s recommendations. All samples were analyzed in triplicate.
Fluorescent labeling was performed with four distinct strategies. Firstly, Exo-FITC (SBI;
Mountain View, CA) was employed to quantitate urine exosomes amongst our particle
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populations. Exosomes are a type of extracellular microvesicle (EMV) with a diameter range
(30–200 nm) that overlaps with the size range of CNP (80–500 nm). Exosomes are generally
defined as being endocytic in origin, produced by the inward budding of multivesicular bodies
(MVBs). They are released from the cell into the microenvironment following fusion of MVBs
with the plasma membrane. Exo-FITC is a commercially available universal and reversible
exosome label that relies on the unique surface characteristics of exosomes to achieve binding.
Exosome positive controls, derived from cultured human cells, were generously donated by
the Nolta Lab (Center for Regenerative Cures, UC Davis School of Medicine, Davis, CA,
USA). Secondly, Fluo-4 (CNP) and Fluo-4-AM (exosomal controls) were used to selectively
label particulates with high calcium content as has been previously reported by others[32].
Labeled calcium indicators are molecules that exhibit an increase in fluorescence upon binding
Ca2+. Fluo-3 has long been used to image the spatial dynamics of Ca2+ signaling in cell biology.
Fluo-4 is an analog of Fluo-3 with the two chlorine substituents replaced by fluorines, which
results in increased fluorescence excitation at 488nm and consequently higher fluorescence
signal levels. Lastly, two different molecules that selectively and specifically bind to calcium-
phosphorus surfaces (alendronate, osteopontin) were conjugated to a fluorophor. Fluorophor
labeling was performed with a commercially available kit (Lightning Link1 Rapid Dylight1
488 conjugation kit; Innova Bioscience, Babraham, UK) designed for this purpose according
to the manufacturer’s recommendations. Alendronate sodium hydrate was obtained from
Cayman Chemicals (Ann Arbor, MI, USA) and recombinant mouse osteopontin was obtained
from R&D Systems (Minneapolis, MN, USA).
All samples were diluted in 0.9% saline (Baxter) that had been sequentially filtered thru 0.8,
0.2, 0.1, and 0.02 syringe filters (Whatman) to remove background particulate matter. Each
sample was analyzed under two conditions. On the first run through the NTA the fluorescent
long-pass filter was left out of the path to the camera. Thus, one first captured the characteris-
tics of all the suspended particles in the 30–2000 nm size range. Next, the long-pass filter was
placed in line and the characteristics of only the fluoro-labeled sub-population (i.e. CNP) was
captured. All plasticware was rinsed with this same saline prior to usage. NTA was used to con-
firm the absence of detectable particulates after each saline batch was generated. NTA calibra-
tion was performed monthly according to manufacturer’s recommendations.
All data files were compiled and maintained using an open-source office suite (LibreOf-
fice5). Because transmission electron microscopy (TEM) is considered the gold standard for
the identification of CNP, TEM was performed on the in vitro synthesized CNP stock solutions
as described above. TEM studies were also performed to identify CNP formed in vivo in the
urine of healthy, colony cats. In each case 5 microliters of samples were applied to a coated
copper mesh and excess fluid wicked away. After complete air-drying, each prepared mesh
was inspected with electron microscopy at 80KV.
Results
Submicron particulates in normal feline urine
Using laser light-scatter mode, the NTA consistently identified a population of submicron par-
ticles within the CNP size range. Summary results from the 9 cats are presented in Table 1 and
a representative histogram is shown in Fig 1.
As shown in Table 1, the mode of the diameter measurements is typical for what has been
reported for primary CNP by other modalities such as dynamic light scattering[16] and the
size range (10th to 90th percentile) lies well within the reported size range of CNP [33]. The his-
togram is suggestive of a sample in which a subset of CNP has undergone transition to larger
forms (secondary CNP) and the size of the larger forms is consistent with prior reports[16].
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As the size of this particle population is also consistent with exosomes, it is important to
exclude these extracellular vesicles from the analysis. Staining of feline urine samples with
Exo-FITC1 resulted in no detectable particle population using NTA fluorescence mode. As a
positive control, exosomes derived from cultured human cells and concentrated with precipi-
tation methods (ExoQuick1) were readily identified at concentrations as low as 1 x107 parti-
cles per milliliter (data not shown). Moreover, the number of presumptive CNP identified in
light-scatter mode is orders of magnitude larger than has been previously reported for urinary
exosomes in humans[30]. Lastly, the refractive index (RI) of exosomes in human urine is
reported to be on the order of 1.37 [27] whereas the particles identified in feline urine have an
RI that is 3–10 times greater.
To determine whether the particle populations observed contained a calcium-rich outer
shell as is typical of CNP, we repeated NTA analysis in the presence of Fluo-4-AM at a final
concentration of 1 mM. In each sample, the predominant particulate population was strongly
positive for Fluo-4-AM indicating calcium content well in excess of background levels. A rep-
resentative summary histogram (left) and individual analyses from the triplicate assessment
for cat #1 is shown in Fig 2.
One of the defining features of CNP has been their ability to increase in number under suit-
able, cell-free conditions [34]. This spontaneous formation in cell-free culture media was one
of the original features that led to them being named nanobacteria and presumed to be living
organisms. In cell culture media, this expansion in number occurs slowly taking a matter of
Table 1. Characteristic of submicron particulates in healthy cat urine (n = 9).
Diameter Diameter Diameter Diameter Diameter Concentration
(nm) (nm) (nm) (nm) (nm) (1010 per mL)
mean mode 10th 50th 90th
Mean 165.22 68.78 51.56 114.11 340.67 2.75
SE 9.90 8.44 4.32 11.44 31.72 0.24
Mean and mode as well as values for the 10th, 50th, and 90th percentile are shown. In addition, concentration in particles (x1010) per mL of undiluted urine is
presented.
doi:10.1371/journal.pone.0166045.t001
Fig 1. Representative histogram showing size distribution and cumulative percentage (left) of submicron
particulate matter in urine from healthy cats. A representative frame from the captured video analyzed by NTA is shown
as well (right).
doi:10.1371/journal.pone.0166045.g001
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weeks. In previous in vitro studies, CNP numbers (and average size) have been shown to
increase substantially within a matter of hours. For each of our 9 urine samples, analysis was
repeated after a 4 hr incubation at 37 deg C. The results of this analysis are shown in Table 2
and a representative data set is displayed in Fig 3. Particulate concentrations increased approx-
imately 4-fold during this incubation period and both the median as well as the mode of the
particle diameters increased suggesting both a substantial number of new particles forming as
well as an increase in their size. This increase in both particle number and size was inhibited
by the addition of a calcium chelator (citrate) to the samples (data not shown).
Specific binding of fluorophor-conjugated alendronate and osteopontin
Primary CNP consist of an inner cavity surrounded by a hydroxyapatite outer shell. Larger
secondary CNP may increase in size following the acquisition of an additional outer layer of
protein (e.g. fetuin-a) or mucus (which can be detected by staining with 2% uranyl acetate)
[23]. Thus, primary CNP, but rarely secondary CNP should specifically bind to agents with
affinity for hydroxyapatite surfaces. To exploit this property we fluorescently labeled two such
agents (alendronate, a bisphosphonate compound, and osteopontin, a hydroxyapatite-binding
protein expressed in bone) and treated all feline urine samples with these compounds prior to
repeating NTA in fluorescence mode. With both agents, specific binding to the nanoparticu-
lates present in feline urine was observed (Fig 4A and 4B) while no such binding was observed
with polystyrene control beads (100 nm mean diameter). Preferential binding to primary CNP
Fig 2. Fluo-4-AM positive particulate matter from a healthy cat. A representative histogram showing averaged sizing and relative
abundance data (with SE in red) and individual analyses from the triplicate assessment (right) cumulative percentage (left) of submicron
particulate matter in healthy feline urine.
doi:10.1371/journal.pone.0166045.g002
Table 2. Characteristic of submicron particulates in healthy cat urine (n = 9) after a 4 hr incubation at 37 deg C.
Diameter Diameter Diameter Diameter Diameter Concentration
(nm) (nm) (nm) (nm) (nm) (1010 per mL)
mode mode 10th 50th 90th
Mean 142.11 114.44 71.89 131.22 222.78 10.39
SE 9.90 8.44 4.32 11.44 31.72 0.98
Mean and mode as well as values for the 10th, 50th, and 90th percentile are shown. In addition, concentration in particles (x1010) per mL of undiluted urine is
presented.
doi:10.1371/journal.pone.0166045.t002
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is detected by the shift in the histogram to the left (smaller sized population). CNP generated
in vitro cannot acquire this mucus layer and larger CNP retain the ability to bind alendronate
(Fig 5). Transmission electron microscopy was used to characterize the urine particulates in
parallel with NTA evaluation (Fig 6).
Discussion
Submicron particulate matter appears to be relatively abundant in feline urine as evidenced by
NTA of the samples we analyzed. In our nine cats with no known history of urolithiasis, the
average concentration of submicron particulates was 2.7 +/- 0.21 x1010 particles per milliliter
of urine. Several lines of evidence suggest strongly that this particulate matter is largely miner-
alo-organic and not exosomal in nature. While urine exosomes are quite numerous and repre-
sent an important potential source of novel biomarkers, exosomes would generally require
specific induction (e.g. with antidiuretic hormone) or post-acquisition enrichment to reach
the concentrations in mammalian urine observed herein.
We have demonstrated that the submicron particulates present in feline urine fall within
established ranges for CNP and have the characteristic structural features of CNP in TEM
images. In our feline samples the 10th to the 90th percentile of particle diameter averaged at
54–362 nm, which is entirely consistent with CNP sizes established by other modalities. How-
ever, NTA has several advantages over other reported methods for CNP analysis (e.g. dynamic
light scattering among others) and can be coupled with fluorescent labeling to allow for immu-
nophenotyping of submicron particle sub-populations. CNP are mineralo-organic colloidally
suspended particles that play a role in both physiologic mineral homeostasis as well as in dis-
eases characterized by ectopic extra-skeletal mineralization. Of particular importance is the
potential role of CNP in urinary tract lithogenesis. CNP have been isolated from uroliths, Ran-
dall’s plaques, and bladder mucosa in encrusted urinary bladder cystitis[18–24]. NTA can
characterize particle populations ranging from 30–1000 nm in size and requires as little as one
microliter of biological fluid sample. This minute sample size requirement may allow for inves-
tigations to be performed in other urolithiasis models wherein urine volumes are exceedingly
small such as Drosophila sp.[35,36].
Size distribution alone is insufficient to establish these nanoparticulates as CNP. We have
demonstrated that under sterile, cell-free conditions these particulates can increase in number
Fig 3. Representative histogram showing size distribution and cumulative percentage (left) of submicron
particulate matter from urine obtained from a healthy cat. After a 4 hr incubation at 37 deg C. A representative frame
from the captured video analyzed by NTA is shown as well (right).
doi:10.1371/journal.pone.0166045.g003
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nearly 4-fold which is consistent with the behavior described for CNP generated in vitro by
others[16]. Further, due to the overlap of the CNP size range with that for exosomes it is essen-
tial to distinguish these two nanoparticulate populations. While the refractive index (RI) of the
submicron particulates in feline urine is much greater than is reported for urinary exosomes,
the investigators deemed that this alone was insufficient to exclude exosomes from the analy-
sis. For this reason, NTA following staining with a specific and reversible exosome-binding
fluorophore (Exo-FITC1) was performed as well. At the urine dilutions used in this study,
Exo-FITC staining particles were below the detection limit for NTA. Human exosomal prepa-
rations were detectable at concentrations as low as 1x107 particles/mL. Given the high RI of
the particles of interest in our samples and the lack of Exo-FITC1 binding, the authors con-
cluded that exosomes make up only a very minor portion of the particle populations in our
samples. Moreover, the submicron particle identified with electron microscopy lack the char-
acteristic cup shape of exosomes. Further, the increase in size was inhibited by the addition of
Fig 4. A: Representative histogram showing size distribution and cumulative percentage (left) of submicron particulate
matter in healthy feline urine after labeling with DyLight 488 conjugated alendronate. A representative frame from the
captured video analyzed by NTA is shown as well (right). Note the strongly preferential binding to primary CNP that lack an
outer layer of protein or mucus. B: Representative histogram showing averaged sizing and relative abundance data (left; SE
in red) and individual analyses from the assessment (right) of this representative sample of healthy feline urine after labeling
with DyLight 488 conjugated osteopontin. Note the strongly preferential binding to primary naturally-occurring CNP that lack
an outer layer of protein or mucus.
doi:10.1371/journal.pone.0166045.g004
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the chelator citrate, which has also been reported to help inhibit urinary crystallite deposition
and CaOx stone formation[37].
Fluo-4 is a calcium-activated fluorophore that has been used previously to detect nanoscale
calcium-containing crystals[32]. In the present investigation, we employed this agent to con-
firm that the predominant submicron particles present in feline urine have a calcium-rich
outer layer which is strongly supportive of their being CNP. Application of this stain to other
particles notably polystyrene beads) failed to produce particulates detectable by fluorescence
though they were identifiable by laser light scatter.
The outer layer of primary CNP is made up predominately of calcium and phosphorus in
the form of hydroxyapatite (HA). We employed a labeling strategy herein where a fluorophore
Fig 5. DyLight488-conjugated alendronate binding of CNP generated in vitro. A representative histogram showing
averaged sizing and relative abundance data (left; SE in red) and individual analyses from the assessment (right) of this
representative sample in triplicate. Note that CNP generated in vitro do not acquire the protein/mucus coating known to
occur in vivo and the larger forms retain the ability to bind to alendronate.
doi:10.1371/journal.pone.0166045.g005
Fig 6. Transmission electron microscopy (TEM) images of calcifying nanoparticles (CNP). (A) CNP synthesized de
novo in the laboratory using supersatured solutions of calcium and phosphorus and a solution of bovine fetuin A (see detailed
description in the methodology section). (B) CNP identified in the urine of healthy, colony cats. In each case 5 microliters of
samples were applied to a coated copper mesh and excess fluid wicked away. After complete air-drying, each prepared mesh
was evaluated with electron microscopy at 80KV.
doi:10.1371/journal.pone.0166045.g006
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(DyLight488) was conjugated to two compounds that bind specifically to HA, but via different
binding motifs. When these labeled compounds were applied to feline urine samples prior to
NTA, they efficiently and specifically labeled primary CNP. Primary CNP formed in vivo lack
the external coating of protein and mucus that is identified on larger secondary CNP. The
expectation that our labeled products would preferentially bind to the smaller particulates in
our samples was born out by the empiric data. Similarly, when CNP generated in vitro were
subjected to this same analysis no preferential binding to smaller CNP was observed. CNP gen-
erated in vitro can transition to secondary CNP, but lack the protein/mucus coating that can
reduce access to HA surfaces by alendronate and osteopontin.
The limitations of this study bear mentioning. The sample size is modest and limited to a
single mammalian species, which limits the broader applicability of our findings. The authors
elected to not culture the presumptive CNP although this technique has been widely used by
others. While culture techniques offer a means of propagating CNP, they offer no additional
insights into the particle characteristics.
In summary, we have demonstrated that NTA can provide a detailed accounting of the sub-
micron particulate matter in mammalian urine. This method requires as little as 1–5 microli-
ters of urine and is thus suitable for use with even the smallest animal models of urolithiasis
(e.g. fruit flies). The predominant nanoscale particulates in feline urine have the characteristics
of CNP based on their size, their ability to spontaneously form under suitable condition, and
the presence of an outer layer that is rich in calcium and capable of binding to hydroxyapatite
binders such as alendronate and osteopontin. As CNP have been associated with a number of
significant urologic maladies, including nephrolithiasis [38], the method described herein may
prove to be a useful adjunct in evaluating lithogenesis risk in mammals. We propose that uri-
nary CNP indices may prove to be a useful adjunct in the evaluation of lithogenic risk and
future studies evaluating CNP formation in cats and humans with urolithiasis are warranted
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